СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О РОЛИ ГИПЕРУРИКЕМИИ В ПАТОГЕНЕЗЕ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА (Обзор литературы)

TASHKENBAEVA Eleonora Negmatovna; TOGAEV Dilshod Khidirnazarovich; KADIROVA Farzona  Shuhratovna; Ziyadullaev Shuxrat Khudayberdievich

doi:10.26739/2181-9297-2018-2-8

469

Представленный обзор посвящен очень важной и широко обсуждаемой в последнее время в кардиологическом сообществе теме - бессимптомная гиперурикемия как самостоятельный предиктор и патогенетический фактор развития ишемической болезни сердца. Представленные в обзоре данные свидетельствуют о целесообразности разработки методов коррекции бессимптомной гиперурикемии у больных ишемической болезнью сердца

Jurnal nomiБиомедицина ва амалиёт журнали
Nashr soni№ 2 (2018)
Ko'rishlar soni 469

Internet havola https://www.tadqiqot.uz/wp-content/uploads/2018/07/biomedicine/biomedicine-2018-2-47-54.pdf

DOI10.26739/2181-9297-2018-2-8

UzSCI tizimida yaratilgan sana 25-11-2019

O'qishlar soni 411

Nashr sanasi 25-05-2018

Asosiy tilRus

Sahifalar47-54

Kalit so'z

ишемическая болезнь сердца

бессимптомная гиперурикемия

Русский

Представленный обзор посвящен очень важной и широко обсуждаемой в последнее время в кардиологическом сообществе теме - бессимптомная гиперурикемия как самостоятельный предиктор и патогенетический фактор развития ишемической болезни сердца. Представленные в обзоре данные свидетельствуют о целесообразности разработки методов коррекции бессимптомной гиперурикемии у больных ишемической болезнью сердца

Kalit so'z

ишемическая болезнь сердца

бессимптомная гиперурикемия

English

The presented review is devoted to a very important and widely discussed recently in the cardiological community topic - asymptomatic hyperuricemia as an independent predictor and pathogenetic factor of the development of coronary heart disease. The data presented in the review testify to the advisability of developing methods for correcting asymptomatic hyperuricemia in patients with ischemic heart disease.

Kalit so'z

ischemic heart disease

asymptomatic hyperuricemia

Ўзбек

Тақдим етилган адабиётлар шархи кардиологлар хамжамиятида охирги вақтларда кенг мухокама қилинадиган ва ўта мухим мавзуга бағишланган - асимптоматик гиперурикемия юрак ишемик касаллиги ривожланишининг мустақил предиктори ва патогенетик омили. Тадқиқотда келтирилган маълумотлар ишемик юрак касаллиги билан оғриган беморларда асимптоматик гиперурикемияни коррекция усулларини ишлаб чиқишни мақсадга мувофиқлигини тасдиқлайди.

Kalit so'z

юрак ишемик касаллиги

симптомсиз гиперурикемия

№ Muallifning F.I.Sh. Lavozimi Tashkilot nomi

1 TASHKENBAEVA E.N.

2 TOGAEV D.K.

3 KADIROVA F.S.

4 Ziyadullaev S.K.

№ Havola nomi

1 1. Alderman, M. H. (2001). Serum uric acid as a cardiovascular risk factor for heart disease. Current hypertension reports, 3(3), 184-189.

2 2. Alderman, M. H., Cohen, H., Madhavan, S., & Kivlighn, S. (1999). Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension, 34(1), 144-150.

3 3. Anker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., ... & Segal, R. (2003). Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation, 107(15), 1991-1997.

4 4. Baker, J. F., Krishnan, E., Chen, L., & Schumacher, H. R. (2005). Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. The American journal of medicine,118(8), 816-826.

5 5. Brown, A. A., & Hu, F. B. (2001). Dietary modulation of endothelial function: implications for cardiovascular disease–. The American journal of clinical nutrition, 73(4), 673-686.

6 6. Busso N. Mechanisms of inflammation in gout / N. Busso, A. So // Arthritis Research and Therapy. — 2010. — Vol. 12 (2). — P. 206–214.

7 7. Campion, E. W., Glynn, R. J., & Delabry, L. O. (1987). Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. The American journal of medicine, 82(3), 421-426.

8 8. Culleton, B. F., Larson, M. G., Kannel, W. B., & Levy, D. (1999). Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Annals of internal medicine, 131(1), 7-13.

9 9. Djanashiya, P. H., & Didenko, V. A. (2017). YAvlyaetsya li giperurikemiya komponentom metabolicheskogo sindroma? [is hyperuricemia a component of the metabolic syndrome?]. Rossijskiy kardiologicheskiy jurnal, (1), 29-34.

10 10. Tashkenbaeva, E.N., Alavi, A.L., Togaev D.K. (2014). Bessimptomnaya giperurikemiya: patogeneticheskie aspekti, klinika, prognozirovanie, korrekciya [Asymptomatic hyperuricemia: pathogenetic aspects, clinic, predict, correction]. Tashkent. Fan.176

11 11. Fang, J., & Alderman, M. H. (2000). Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. Jama, 283(18), 2404-2410.

12 12. Follow-Up Program Cooperative Group. (1979). Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Jama, 242, 2562-2571.

13 13. Franse, L. V., Pahor, M., Di Bari, M., Shorr, R. I., Wan, J. Y., Somes, G. W., & Applegate, W. B. (2000). Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of hypertension, 18(8), 1149-1154.

14 14. Il’ina, A. E., Barskova, V. G., & Nasonov, E. L. (2008). Bessimptomnaya giperurikemiyapol’za ili vred? [Asymptomatic hyperuricemia-benefit or harm?]. RMJ, 16(24), 1619-1621.

15 15. Il’ina, A. E., Barskova, V. G., & Nasonov, E. L. (2009). Podagra, giperurikemiya i kardiovaskulyarnyj risk [Gout, hyperuricemia and cardiovascular risk]. Nauchno-prakticheskaya revmatologiya, (1)

16 16. Johnson, R. J., Kang, D. H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., ... & Mazzali, M. (2003). Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension, 41(6), 1183-1190.

17 17. Johnson, R. J., Kivlighn, S. D., Kim, Y. G., Suga, S., & Fogo, A. B. (1999). Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. American journal of kidney diseases, 33(2), 225-234.

18 18. Kerkalainen, P., Sarlund, H., & Laakso, M. (1999). Long–term association of cardiovascular events in successfully treated hypertensive patients. Hypertension, 39, 144-150.

19 19. Kobalava, ZH. D., Tolkacheva, V. V., & Karaulova, YU. L. (2002). Mochevaya kislota-marker i/ili novyj faktor riska razvitiya serdechno-sosudistyh oslozhneniy [Uric acid marker and / or a new risk factor for cardiovascular events]. Rus. med. jurn, 10(10), 431-437.

20 20. Kutzing, M. K., & Firestein, B. L. (2008). Altered uric acid levels and disease states. Journal of Pharmacology and Experimental Therapeutics, 324(1), 1-7.

21 21. Lebedeva, M. V., Stahova, T. YU., Minakova, E. G., Zajceva, L. I., Severova, M. M., & Pulin, A. A. (2010). Funkciya ehndoteliya u bol’nyh s arterial’noj gipertenziej i narusheniem obmena mochevoy kisloti [Endothelial function in patients with arterial hypertension and impaired uric acid metabolism]. Vestnik Rossijskoy akademii medicinskih nauk, (12), 44-46.

22 22. Leyva, F., Anker, S. D., Godsland, I. F., Teixeira, M., Hellewell, P. G., Kox, W. J., ... & Coats, A. J. S. (1998). Uric acid in chronic heart failure: a marker of chronic inflammation. European heart journal, 19(12), 1814-1822

23 23. Lowe, L. P., Liu, K., Greenland, P., Metzger, B. E., Dyer, A. R., & Stamler, J. (1997). Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. Diabetes Care,20(2), 163-169.

24 24. Madar, Z., Kalet-Litman, S., & Stark, A. H. (2005). Inducible nitric oxide synthase activity and expression in liver and hepatocytes of diabetic rats. Pharmacology, 73(2), 106-112.

25 25. Mazzali, M., Kanellis, J., Han, L., Feng, L., Xia, Y. Y., Chen, Q., ... & Lan, H. Y. (2002). Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.American Journal of Physiology-Renal Physiology, 282(6), F991-F997.

26 26. Messerli, F. H. (1996). : Left ventricular hypertrophy and its regression. Ed. FH Messerli.

27 27. Mitsuhashi, H., Yatsuya, H., Matsushita, K., Zhang, H., Otsuka, R., Muramatsu, T., ... & Toyoshima, H. (2009). Uric acid and left ventricular hypertrophy in Japanese men. Circulation Journal, 73(4), 667-672.

28 28. Morris, M. S. (2001). National health and nutrition examination survey. Hyperhomocysteinemia associated with poor recall in the third national health and nutrition examination survey. Am J Clin Nutr, 73, 927-933.

29 29. Nakagawa, T., Hu, H., Zharikov, S., Tuttle, K. R., Short, R. A., Glushakova, O., ... & Patel, J. M. (2006). A causal role for uric acid in fructose-induced metabolic syndrome. American Journal of Physiology-Renal Physiology, 290(3), F625-F631.

30 30. Neogi, T. (2008). Asymptomatic hyperuricemia: perhaps not so benign?. The Journal of rheumatology, 35(5), 734-737

31 31. Reaven, G. (2002). Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation,106(3), 286-288.

32 32. Ruilope, L. M., & Garcia-Puig, J. (2001). Hyperuricemia and renal function. Current hypertension reports, 3(3), 197-202.

33 33. Verdecchia, P., Porcellati, C., Schillaci, G., Borgioni, C., Ciucci, A., Battistelli, M., ... & Santucci, C. (1994). Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension, 24(6), 793-801.

34 34. Verdecchia, P., Schillaci, G., Reboldi, G., Santeusanio, F., Porcellati, C., & Brunetti, P. (2000). Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension, 36(6), 1072-1078.

35 35. Wannamethee, S. G. (2001). Serum uric acid is not an independent risk factor for coronary heart disease. Current Hypertension Reports, 3(3), 190-196.

36 36. Waring, W. S., McKnight, J. A., Webb, D. J., & Maxwell, S. R. J. (2007). Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia, 50(12), 2572-2579.

Kutilmoqda

№	Muallifning F.I.Sh.	Lavozimi	Tashkilot nomi
1	TASHKENBAEVA E.N.
2	TOGAEV D.K.
3	KADIROVA F.S.
4	Ziyadullaev S.K.

№	Havola nomi
1	1. Alderman, M. H. (2001). Serum uric acid as a cardiovascular risk factor for heart disease. Current hypertension reports, 3(3), 184-189.
2	2. Alderman, M. H., Cohen, H., Madhavan, S., & Kivlighn, S. (1999). Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension, 34(1), 144-150.
3	3. Anker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., ... & Segal, R. (2003). Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation, 107(15), 1991-1997.
4	4. Baker, J. F., Krishnan, E., Chen, L., & Schumacher, H. R. (2005). Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. The American journal of medicine,118(8), 816-826.
5	5. Brown, A. A., & Hu, F. B. (2001). Dietary modulation of endothelial function: implications for cardiovascular disease–. The American journal of clinical nutrition, 73(4), 673-686.
6	6. Busso N. Mechanisms of inflammation in gout / N. Busso, A. So // Arthritis Research and Therapy. — 2010. — Vol. 12 (2). — P. 206–214.
7	7. Campion, E. W., Glynn, R. J., & Delabry, L. O. (1987). Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. The American journal of medicine, 82(3), 421-426.
8	8. Culleton, B. F., Larson, M. G., Kannel, W. B., & Levy, D. (1999). Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Annals of internal medicine, 131(1), 7-13.
9	9. Djanashiya, P. H., & Didenko, V. A. (2017). YAvlyaetsya li giperurikemiya komponentom metabolicheskogo sindroma? [is hyperuricemia a component of the metabolic syndrome?]. Rossijskiy kardiologicheskiy jurnal, (1), 29-34.
10	10. Tashkenbaeva, E.N., Alavi, A.L., Togaev D.K. (2014). Bessimptomnaya giperurikemiya: patogeneticheskie aspekti, klinika, prognozirovanie, korrekciya [Asymptomatic hyperuricemia: pathogenetic aspects, clinic, predict, correction]. Tashkent. Fan.176
11	11. Fang, J., & Alderman, M. H. (2000). Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. Jama, 283(18), 2404-2410.
12	12. Follow-Up Program Cooperative Group. (1979). Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Jama, 242, 2562-2571.
13	13. Franse, L. V., Pahor, M., Di Bari, M., Shorr, R. I., Wan, J. Y., Somes, G. W., & Applegate, W. B. (2000). Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of hypertension, 18(8), 1149-1154.
14	14. Il’ina, A. E., Barskova, V. G., & Nasonov, E. L. (2008). Bessimptomnaya giperurikemiyapol’za ili vred? [Asymptomatic hyperuricemia-benefit or harm?]. RMJ, 16(24), 1619-1621.
15	15. Il’ina, A. E., Barskova, V. G., & Nasonov, E. L. (2009). Podagra, giperurikemiya i kardiovaskulyarnyj risk [Gout, hyperuricemia and cardiovascular risk]. Nauchno-prakticheskaya revmatologiya, (1)
16	16. Johnson, R. J., Kang, D. H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., ... & Mazzali, M. (2003). Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension, 41(6), 1183-1190.
17	17. Johnson, R. J., Kivlighn, S. D., Kim, Y. G., Suga, S., & Fogo, A. B. (1999). Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. American journal of kidney diseases, 33(2), 225-234.
18	18. Kerkalainen, P., Sarlund, H., & Laakso, M. (1999). Long–term association of cardiovascular events in successfully treated hypertensive patients. Hypertension, 39, 144-150.
19	19. Kobalava, ZH. D., Tolkacheva, V. V., & Karaulova, YU. L. (2002). Mochevaya kislota-marker i/ili novyj faktor riska razvitiya serdechno-sosudistyh oslozhneniy [Uric acid marker and / or a new risk factor for cardiovascular events]. Rus. med. jurn, 10(10), 431-437.
20	20. Kutzing, M. K., & Firestein, B. L. (2008). Altered uric acid levels and disease states. Journal of Pharmacology and Experimental Therapeutics, 324(1), 1-7.
21	21. Lebedeva, M. V., Stahova, T. YU., Minakova, E. G., Zajceva, L. I., Severova, M. M., & Pulin, A. A. (2010). Funkciya ehndoteliya u bol’nyh s arterial’noj gipertenziej i narusheniem obmena mochevoy kisloti [Endothelial function in patients with arterial hypertension and impaired uric acid metabolism]. Vestnik Rossijskoy akademii medicinskih nauk, (12), 44-46.
22	22. Leyva, F., Anker, S. D., Godsland, I. F., Teixeira, M., Hellewell, P. G., Kox, W. J., ... & Coats, A. J. S. (1998). Uric acid in chronic heart failure: a marker of chronic inflammation. European heart journal, 19(12), 1814-1822
23	23. Lowe, L. P., Liu, K., Greenland, P., Metzger, B. E., Dyer, A. R., & Stamler, J. (1997). Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. Diabetes Care,20(2), 163-169.
24	24. Madar, Z., Kalet-Litman, S., & Stark, A. H. (2005). Inducible nitric oxide synthase activity and expression in liver and hepatocytes of diabetic rats. Pharmacology, 73(2), 106-112.
25	25. Mazzali, M., Kanellis, J., Han, L., Feng, L., Xia, Y. Y., Chen, Q., ... & Lan, H. Y. (2002). Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.American Journal of Physiology-Renal Physiology, 282(6), F991-F997.
26	26. Messerli, F. H. (1996). : Left ventricular hypertrophy and its regression. Ed. FH Messerli.
27	27. Mitsuhashi, H., Yatsuya, H., Matsushita, K., Zhang, H., Otsuka, R., Muramatsu, T., ... & Toyoshima, H. (2009). Uric acid and left ventricular hypertrophy in Japanese men. Circulation Journal, 73(4), 667-672.
28	28. Morris, M. S. (2001). National health and nutrition examination survey. Hyperhomocysteinemia associated with poor recall in the third national health and nutrition examination survey. Am J Clin Nutr, 73, 927-933.
29	29. Nakagawa, T., Hu, H., Zharikov, S., Tuttle, K. R., Short, R. A., Glushakova, O., ... & Patel, J. M. (2006). A causal role for uric acid in fructose-induced metabolic syndrome. American Journal of Physiology-Renal Physiology, 290(3), F625-F631.
30	30. Neogi, T. (2008). Asymptomatic hyperuricemia: perhaps not so benign?. The Journal of rheumatology, 35(5), 734-737
31	31. Reaven, G. (2002). Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation,106(3), 286-288.
32	32. Ruilope, L. M., & Garcia-Puig, J. (2001). Hyperuricemia and renal function. Current hypertension reports, 3(3), 197-202.
33	33. Verdecchia, P., Porcellati, C., Schillaci, G., Borgioni, C., Ciucci, A., Battistelli, M., ... & Santucci, C. (1994). Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension, 24(6), 793-801.
34	34. Verdecchia, P., Schillaci, G., Reboldi, G., Santeusanio, F., Porcellati, C., & Brunetti, P. (2000). Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension, 36(6), 1072-1078.
35	35. Wannamethee, S. G. (2001). Serum uric acid is not an independent risk factor for coronary heart disease. Current Hypertension Reports, 3(3), 190-196.
36	36. Waring, W. S., McKnight, J. A., Webb, D. J., & Maxwell, S. R. J. (2007). Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia, 50(12), 2572-2579.